TScan Therapeutics, Inc.
TCRX
$1.60
-$0.12-6.98%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -36.61% | 95.71% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -36.61% | 95.71% | |||
| Cost of Revenue | -378.54% | -2.29% | |||
| Gross Profit | 392.77% | 4.28% | |||
| SG&A Expenses | 8.29% | -4.68% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 11.01% | -2.83% | |||
| Operating Income | -12.54% | 4.37% | |||
| Income Before Tax | -19.81% | 5.60% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -19.81% | 5.60% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -19.81% | 5.60% | |||
| EBIT | -12.54% | 4.37% | |||
| EBITDA | -13.95% | 4.25% | |||
| EPS Basic | -12.96% | 6.34% | |||
| Normalized Basic EPS | -9.51% | 6.34% | |||
| EPS Diluted | -12.96% | 6.34% | |||
| Normalized Diluted EPS | -9.51% | 6.34% | |||
| Average Basic Shares Outstanding | 6.07% | 0.80% | |||
| Average Diluted Shares Outstanding | 6.07% | 0.80% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||